MG
MLYS icon

Michael Gelband’s Mineralys Therapeutics MLYS Stock Holding History

Michael Gelband’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.73M Buy
+101,052
New +$2.77M 0.02% 700
2025
Q4 		– Sell
-6,670
Closed -$253K – 1860
2025
Q3 		$253K Sell
6,670
-165,882
-96% -$3.59M ﹤0.01% 1339
2025
Q2 		$2.33M Buy
+172,552
New +$2.5M 0.02% 687
2024
Q3 		– Sell
-274,316
Closed -$3.21M – 1904
2024
Q2 		$3.21M Buy
274,316
+152,110
+124% +$1.92M 0.02% 598
2024
Q1 		$1.58M Buy
122,206
+48,266
+65% +$596K 0.01% 798
2023
Q4 		$636K Sell
73,940
-85,501
-54% -$671K ﹤0.01% 966
2023
Q3 		$1.52M Sell
159,441
-34,084
-18% -$444K 0.01% 788
2023
Q2 		$3.3M Buy
193,525
+12,213
+7% +$183K 0.03% 599
2023
Q1 		$2.84M Buy
+181,312
New +$3.05M 0.02% 742

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Michael Gelband's MLYS Position: Q2 2026 in Review

Michael Gelband opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 101,052 shares worth $2.73M. The stake represents 0.02% of the portfolio and ranks #700 among its holdings. This is a return to the name: Michael Gelband previously reported a position in MLYS as recently as Q3 2025.

Michael Gelband first reported a position in MLYS in Q1 2023 and has held it in 9 quarters since. The position peaked at $3.3M in Q2 2023. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Michael Gelband held 101,052 shares of Mineralys Therapeutics worth $2.73M as of Q2 2026.
  • Mineralys Therapeutics was a new Michael Gelband position in Q2 2026.
  • Mineralys Therapeutics made up 0.02% of Michael Gelband's portfolio in Q2 2026, its #700 holding.
  • Michael Gelband first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 9 quarters since.
  • Michael Gelband's Mineralys Therapeutics position peaked at $3.3M in Q2 2023.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.